BioCentury
ARTICLE | Clinical News

SB623: Phase II started

September 26, 2016 7:00 AM UTC

In July, SanBio began the double-blind, sham-controlled, U.S. and Japanese Phase II STEMTRA trial to evaluate 2.5, 5 and 10 million SB623 cells surgically implanted adjacent to the injured cerebral re...